KFA
ABBV icon

Krane Funds Advisors’s AbbVie ABBV Stock Holding History

Krane Funds Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$706K Buy
3,418
+1,452
+74% +$322K 0.03% 109
2025
Q4 		$449K Buy
1,966
+269
+16% +$61.3K 0.01% 112
2025
Q3 		$388K Sell
1,697
-546
-24% -$111K 0.01% 113
2025
Q2 		$416K Buy
2,243
+584
+35% +$109K 0.02% 80
2025
Q1 		$348K Sell
1,659
-338
-17% -$65.7K 0.01% 82
2024
Q4 		$355K Sell
1,997
-185
-8% -$34K 0.01% 72
2024
Q3 		$431K Buy
2,182
+65
+3% +$12.1K 0.02% 58
2024
Q2 		$363K Sell
2,117
-148
-7% -$24.5K 0.02% 73
2024
Q1 		$407K Sell
2,265
-694
-23% -$120K 0.02% 80
2023
Q4 		$459K Buy
2,959
+1,142
+63% +$166K 0.02% 74
2023
Q3 		$271K Sell
1,817
-3,161
-63% -$464K 0.01% 97
2023
Q2 		$671K Buy
4,978
+1,469
+42% +$215K 0.04% 33
2023
Q1 		$566K Buy
+3,509
New +$536K 0.03% 55
2022
Q3 		– Sell
-1,866
Closed -$286K – 118
2022
Q2 		$286K Buy
+1,866
New +$285K 0.01% 172

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Krane Funds Advisors's ABBV Position: Q1 2026 in Review

Krane Funds Advisors increased its AbbVie (ABBV) stake by 74% in Q1 2026, buying an estimated $322K and bringing the position to 3,418 shares worth $706K. The position accounts for 0.03% of the portfolio, ranked #109.

Krane Funds Advisors first reported a position in ABBV in Q2 2022 and has held it in 14 quarters since. 4,074 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Krane Funds Advisors held 3,418 shares of AbbVie worth $706K as of Q1 2026.
  • Krane Funds Advisors bought 1,452 AbbVie shares in Q1 2026, an estimated $322K.
  • AbbVie made up 0.03% of Krane Funds Advisors's portfolio in Q1 2026, its #109 holding.
  • Krane Funds Advisors first reported a position in AbbVie in Q2 2022 and has held it in 14 quarters since.
  • 4,074 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Krane Funds Advisors's 13F filing for Q1 2026, filed 11 May 2026.